^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AMG 172

    i
    Other names: AMG 172
    Associations

    News

    Trials
    Company:
    Amgen
    Drug class:
    Microtubule inhibitor, CD70-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    4years
    First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma. (PubMed, Cancer Chemother Pharmacol)
    AMG 172 exhibited a favorable pharmacokinetic profile in patients with relapsed/refractory ccRCC and showed evidence suggestive of limited antitumor activity. Safety and tolerability were as expected for a maytansinoid antibody-drug conjugate.
    Clinical • P1 data • PK/PD data • Journal
    |
    CD70 (CD70 Molecule)
    |
    AMG 172